Immuron Ltd
Research Immuron Ltd (IMRN) on Bullrun: market cap USD 6.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMRN
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.53M
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 6.53M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.35M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 9.74M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.71M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 11.85M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 14.24M | n/a | n/a | n/a |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immuron Ltd's market cap?
Immuron Ltd's market capitalization is USD 6.53M.
What does Immuron Ltd do?
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.